Description
Manufacturer:
Sanofi India Ltd
Salt Composition:
Glimepiride (1mg)
Description:
Amaryl 1mg Tablet belongs to the sulfonylurea group of medicines and is used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels, reducing the risk of serious complications such as kidney damage, blindness, nerve problems, and loss of limbs. This medication may be used alone or in combination with other diabetes medicines. It should be taken just before or with the first meal of the day, and consistency in timing is important for maximum effectiveness. The doctor will determine the appropriate dose based on blood sugar levels, which may be adjusted over time.
Even if blood sugar levels are controlled, it is crucial to continue taking Amaryl 1mg Tablet as prescribed, as stopping it without medical advice can lead to a rise in blood sugar and increase the risk of diabetes-related complications. However, medication alone is not enough?maintaining a healthy lifestyle with a balanced diet, regular exercise, and weight management is also essential in diabetes control.
Common side effects of Amaryl 1mg Tablet include low blood sugar (hypoglycemia), nausea, headache, weakness, dizziness, and possible weight gain. Symptoms of low blood sugar, such as sweating, dizziness, headache, and shaking, should be recognized and managed by consuming fast-acting sources of glucose like sugary foods or fruit juice. Alcohol should be avoided as it can further lower blood sugar levels.
This medicine is not suitable for individuals with type 1 diabetes, diabetic ketoacidosis, or severe kidney or liver disease. Before taking Amaryl 1mg Tablet, patients should inform their doctor about any history of heart disease, thyroid disorders, or other hormonal conditions. Pregnant or breastfeeding women should also seek medical advice before using this medication. Regular monitoring of blood sugar levels and periodic blood tests to check blood cell counts and liver function may be recommended by the doctor.
Reviews
There are no reviews yet.